PERSPECTA

News from every angle

← Back to headlines

Neurocrine Reaffirms INGREZZA Outlook and Soleno Acquisition Timeline

Neurocrine Biosciences reaffirmed its financial outlook for INGREZZA, projecting $2.7 billion to $2.8 billion. The company also confirmed that its acquisition of Soleno Therapeutics is on track to close in the second quarter.

6 May, 02:33 — 6 May, 02:33
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed103d ago

Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close

Read full article →

Related Stories

Dutch Sports Car Manufacturer Spyker Returns with New Model

23m ago

Virgin Secures Track Access for Eurostar Rival Launch in 2030

30m ago

Aston Martin Invests $2 Million in Survival Strategy

52m ago

Norway Wealth Fund and ECB Warn of AI-Driven Stock Market Bubble

54m ago